EA202091166A1 - ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ - Google Patents
ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙInfo
- Publication number
- EA202091166A1 EA202091166A1 EA202091166A EA202091166A EA202091166A1 EA 202091166 A1 EA202091166 A1 EA 202091166A1 EA 202091166 A EA202091166 A EA 202091166A EA 202091166 A EA202091166 A EA 202091166A EA 202091166 A1 EA202091166 A1 EA 202091166A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- binding polypeptides
- altered glycosylation
- antigen
- polypeptides containing
- effective function
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361776715P | 2013-03-11 | 2013-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091166A1 true EA202091166A1 (ru) | 2021-04-30 |
Family
ID=50278674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091166A EA202091166A1 (ru) | 2013-03-11 | 2013-09-12 | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ |
| EA201590545A EA035987B1 (ru) | 2012-09-12 | 2013-09-12 | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ АФФИННОСТЬЮ К Fc-ГАММА РЕЦЕПТОРАМ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590545A EA035987B1 (ru) | 2012-09-12 | 2013-09-12 | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ АФФИННОСТЬЮ К Fc-ГАММА РЕЦЕПТОРАМ |
Country Status (34)
| Country | Link |
|---|---|
| EP (3) | EP4223783A3 (https=) |
| JP (1) | JP6438397B2 (https=) |
| KR (3) | KR102185151B1 (https=) |
| CN (2) | CN104797601B (https=) |
| AU (1) | AU2013315499B2 (https=) |
| CA (1) | CA2884762C (https=) |
| CL (1) | CL2015000606A1 (https=) |
| CR (1) | CR20150147A (https=) |
| CY (1) | CY1120909T1 (https=) |
| DK (2) | DK3366705T5 (https=) |
| DO (1) | DOP2015000050A (https=) |
| EA (2) | EA202091166A1 (https=) |
| EC (1) | ECSP15014133A (https=) |
| ES (2) | ES2684549T3 (https=) |
| FI (1) | FI3366705T3 (https=) |
| HR (2) | HRP20181354T1 (https=) |
| HU (2) | HUE062876T2 (https=) |
| IL (4) | IL237640B (https=) |
| LT (2) | LT3366705T (https=) |
| MA (1) | MA37949B1 (https=) |
| MX (2) | MX366103B (https=) |
| MY (1) | MY170126A (https=) |
| NZ (1) | NZ705983A (https=) |
| PE (1) | PE20150650A1 (https=) |
| PH (1) | PH12015500528A1 (https=) |
| PL (2) | PL3366705T3 (https=) |
| PT (2) | PT2895513T (https=) |
| RS (2) | RS57748B1 (https=) |
| SG (2) | SG11201501521TA (https=) |
| SI (2) | SI2895513T1 (https=) |
| TN (1) | TN2015000085A1 (https=) |
| UA (1) | UA116995C2 (https=) |
| WO (1) | WO2014043361A1 (https=) |
| ZA (1) | ZA201501417B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| US9701753B2 (en) | 2013-03-11 | 2017-07-11 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
| WO2015143091A1 (en) * | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| AU2015243512B2 (en) | 2014-04-08 | 2020-06-04 | University Of Georgia Research Foundation Inc. | Site-specific antibody-drug glycoconjugates and methods |
| WO2015191883A1 (en) * | 2014-06-12 | 2015-12-17 | Dophen Biomedical | Homogenous antibody drug conjugates via enzymatic methods |
| CA3205824A1 (en) * | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3222292A1 (en) * | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| LT3538554T (lt) | 2016-11-08 | 2025-10-10 | Antigeną surišantys baltymai, antagonizuojantys leptino receptorius | |
| WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| GB201717446D0 (en) | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
| SG11202005146VA (en) | 2017-12-18 | 2020-06-29 | Regeneron Pharma | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
| PT3773713T (pt) | 2018-04-06 | 2025-07-29 | Regeneron Pharma | Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia |
| JP1640846S (https=) * | 2018-10-16 | 2019-09-09 | ||
| CA3110377A1 (en) | 2018-11-21 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Anti-staphylococcus antibodies and uses thereof |
| PH12021551476A1 (en) | 2018-12-21 | 2022-04-25 | Regeneron Pharma | Rifamycin analogs and antibody-drug conjugates thereof |
| WO2020160242A1 (en) | 2019-02-01 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
| CN114096559B (zh) * | 2019-03-27 | 2026-03-20 | 蒂嘉特克斯公司 | 工程化iga抗体及其使用方法 |
| CN120192414A (zh) | 2019-04-03 | 2025-06-24 | 建新公司 | 具有降低的断裂的抗αβTCR结合多肽 |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| KR20230069969A (ko) | 2020-09-15 | 2023-05-19 | 리제너론 파마슈티칼스 인코포레이티드 | 통증에 대한 lepr 아고니스트의 사용 |
| KR20220052098A (ko) | 2020-10-20 | 2022-04-27 | 주식회사 엘지에너지솔루션 | 마스킹 테이프를 이용한 전극 시편에 대한 물성 측정 시스템 및 이를 이용한 물성 측정 방법 |
| KR102576252B1 (ko) * | 2021-04-07 | 2023-09-11 | 아주대학교산학협력단 | 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물 |
| TW202325273A (zh) * | 2021-10-22 | 2023-07-01 | 美商杜夫特學院信託管理公司 | 靶向fap之中子捕獲劑及與其相關之用途及調配物 |
| KR20250058123A (ko) | 2022-07-29 | 2025-04-29 | 리제너론 파마슈티칼스 인코포레이티드 | 항-TfR:페이로드 융합 및 이의 사용 방법 |
| CA3263388A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | VIRAL PARTICLES RETRIBUTED TO TRANSFERRIN RECEPTOR 1 |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| EP4612184A1 (en) | 2022-11-04 | 2025-09-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| AU2023379451A1 (en) | 2022-11-14 | 2025-05-01 | Regeneron Pharmaceuticals, Inc. | Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof |
| KR20250116795A (ko) | 2022-11-14 | 2025-08-01 | 리제너론 파마슈티칼스 인코포레이티드 | 별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법 |
| IL325163A (en) | 2023-06-16 | 2026-02-01 | Regeneron Pharma | CD40 × CD40 dual-specific antigen-binding molecules and their application |
| IL326018A (en) | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
| US20250049896A1 (en) | 2023-07-28 | 2025-02-13 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency |
| TW202535925A (zh) | 2023-10-25 | 2025-09-16 | 比利時商艾伯霖克斯公司 | 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體 |
| TW202540169A (zh) | 2023-11-08 | 2025-10-16 | 法商賽諾菲公司 | 基於ｃｄ２５的溶酶體降解物及其用途 |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| EP4616869A1 (en) * | 2024-03-15 | 2025-09-17 | Oncomatryx Biopharma, S.L. | Fap targeted antibody-drug conjugates |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| BR9606706A (pt) | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| DE69738522T2 (de) | 1996-08-02 | 2009-04-02 | Bristol-Myers Squibb Co. | Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
| DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| DK1562972T3 (da) | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| DK1641823T3 (da) * | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| US8399618B2 (en) * | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| SI1706424T1 (sl) | 2004-01-12 | 2010-01-29 | Applied Molecular Evolution | Variante fc regij |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| WO2006036922A2 (en) * | 2004-09-27 | 2006-04-06 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するＦｃ変異体 |
| BRPI0611445A2 (pt) * | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| PT1896071E (pt) | 2005-06-30 | 2015-07-09 | Janssen Biotech Inc | Métodos e composições com melhorias na atividade terapêutica |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8460364B2 (en) | 2006-07-20 | 2013-06-11 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
| EP2125893A2 (en) * | 2007-01-23 | 2009-12-02 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US20110137011A1 (en) * | 2008-04-21 | 2011-06-09 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
| MX352889B (es) * | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| UY34317A (es) * | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
-
2013
- 2013-09-12 PL PL18166377.4T patent/PL3366705T3/pl unknown
- 2013-09-12 KR KR1020157009038A patent/KR102185151B1/ko active Active
- 2013-09-12 PT PT13766833T patent/PT2895513T/pt unknown
- 2013-09-12 HU HUE18166377A patent/HUE062876T2/hu unknown
- 2013-09-12 EP EP23164492.3A patent/EP4223783A3/en active Pending
- 2013-09-12 KR KR1020207033737A patent/KR102426488B1/ko active Active
- 2013-09-12 SI SI201331144T patent/SI2895513T1/sl unknown
- 2013-09-12 SG SG11201501521TA patent/SG11201501521TA/en unknown
- 2013-09-12 HU HUE13766833A patent/HUE039337T2/hu unknown
- 2013-09-12 CA CA2884762A patent/CA2884762C/en active Active
- 2013-09-12 SI SI201332053T patent/SI3366705T1/sl unknown
- 2013-09-12 MY MYPI2015000513A patent/MY170126A/en unknown
- 2013-09-12 DK DK18166377.4T patent/DK3366705T5/da active
- 2013-09-12 ES ES13766833.1T patent/ES2684549T3/es active Active
- 2013-09-12 EP EP13766833.1A patent/EP2895513B1/en active Active
- 2013-09-12 EP EP18166377.4A patent/EP3366705B1/en active Active
- 2013-09-12 PE PE2015000327A patent/PE20150650A1/es active IP Right Grant
- 2013-09-12 SG SG10201701831VA patent/SG10201701831VA/en unknown
- 2013-09-12 HR HRP20181354TT patent/HRP20181354T1/hr unknown
- 2013-09-12 DK DK13766833.1T patent/DK2895513T3/en active
- 2013-09-12 FI FIEP18166377.4T patent/FI3366705T3/fi active
- 2013-09-12 WO PCT/US2013/059481 patent/WO2014043361A1/en not_active Ceased
- 2013-09-12 PL PL13766833T patent/PL2895513T3/pl unknown
- 2013-09-12 LT LTEP18166377.4T patent/LT3366705T/lt unknown
- 2013-09-12 HR HRP20230623TT patent/HRP20230623T1/hr unknown
- 2013-09-12 EA EA202091166A patent/EA202091166A1/ru unknown
- 2013-09-12 RS RS20180981A patent/RS57748B1/sr unknown
- 2013-09-12 PT PT181663774T patent/PT3366705T/pt unknown
- 2013-09-12 JP JP2015532046A patent/JP6438397B2/ja active Active
- 2013-09-12 CN CN201380058863.8A patent/CN104797601B/zh active Active
- 2013-09-12 LT LTEP13766833.1T patent/LT2895513T/lt unknown
- 2013-09-12 KR KR1020227025572A patent/KR20220110855A/ko not_active Ceased
- 2013-09-12 AU AU2013315499A patent/AU2013315499B2/en active Active
- 2013-09-12 RS RS20230536A patent/RS64317B1/sr unknown
- 2013-09-12 NZ NZ705983A patent/NZ705983A/en unknown
- 2013-09-12 CN CN201910721123.7A patent/CN110590953A/zh active Pending
- 2013-09-12 EA EA201590545A patent/EA035987B1/ru unknown
- 2013-09-12 MA MA37949A patent/MA37949B1/fr unknown
- 2013-09-12 MX MX2015003234A patent/MX366103B/es active IP Right Grant
- 2013-09-12 ES ES18166377T patent/ES2950509T3/es active Active
- 2013-12-09 UA UAA201503410A patent/UA116995C2/uk unknown
-
2015
- 2015-03-02 ZA ZA2015/01417A patent/ZA201501417B/en unknown
- 2015-03-05 DO DO2015000050A patent/DOP2015000050A/es unknown
- 2015-03-06 TN TNP2015000085A patent/TN2015000085A1/fr unknown
- 2015-03-09 IL IL237640A patent/IL237640B/en active IP Right Grant
- 2015-03-11 PH PH12015500528A patent/PH12015500528A1/en unknown
- 2015-03-11 CL CL2015000606A patent/CL2015000606A1/es unknown
- 2015-03-12 MX MX2019007753A patent/MX2019007753A/es unknown
- 2015-03-19 CR CR20150147A patent/CR20150147A/es unknown
- 2015-04-10 EC ECIEPI201514133A patent/ECSP15014133A/es unknown
-
2018
- 2018-08-23 CY CY181100880T patent/CY1120909T1/el unknown
-
2019
- 2019-11-28 IL IL271027A patent/IL271027B/en active IP Right Grant
-
2020
- 2020-08-23 IL IL276866A patent/IL276866B/en unknown
-
2021
- 2021-09-29 IL IL286766A patent/IL286766A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091166A1 (ru) | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
| EA201990017A1 (ru) | Антитела к миостатину и способы их применения | |
| EA201690299A1 (ru) | СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ | |
| EA201891420A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| EA201500208A1 (ru) | Слитые белки, содержащие интерлейкин-10, и их применения | |
| MX2021010354A (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| EA201791253A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| CL2008003784A1 (es) | Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo | |
| MX2016004579A (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| CR10652A (es) | Anticuerpos monoclonales humanos especificos para light humano antagonistas | |
| EA201491494A1 (ru) | Нацеливание на гликаны хондроитинсульфаты | |
| BR112015020885A2 (pt) | polipeptídeos de ligação hiperglicosilados | |
| EA201591814A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc | |
| EA201400488A1 (ru) | Полипептидные конструкции и их применение | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| PH12013500204A1 (en) | Polypeptides for treating and/or limiting influenza infection | |
| BR112015017981A2 (pt) | anticorpo humano específico para metapneumovírus humano, ou fragmento de ligação de antígeno do mesmo, seu uso e composição farmacêutica o compreendendo, bem como ácido nucleico isolado, vetor de expressão recombinante e célula hospedeira | |
| EA201591898A1 (ru) | Антитела, направленные на m-csf | |
| WO2013138259A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
| TH174396A (th) | พอลิเพพไทด์ที่ประกอบด้วย Fc ที่มีไกลโคสิเลชันที่ได้รับการแปรเปลี่ยน และลดการทำงานของเอฟเฟคเตอร์ | |
| EA201792665A1 (ru) | Антитела против ctla-4 и способы их применения | |
| AR090915A1 (es) | Proteina de fusion de proteina linfopoyetina estromal timica canina con la region fc de igg | |
| TH168744A (th) | Cd47 แอนติบอดี และวิธีการใช้มัน | |
| BR112017006203A2 (pt) | anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune. |